Methods and compositions for diagnosis and management of neurodegerative diseases

Patent metadata

Field	Value
Publication number	US-11214835-B1
Application number	US-201816001880-A
Country	US
Kind code	B1
Filing date	Jun 6, 2018
Priority date	Jun 6, 2017
Publication date	Jan 4, 2022
Grant date	Jan 4, 2022

Abstract

Described herein are assays, methods, and devices for diagnosing/prognosing Alzheimer's disease (AD) and/or a neurodegenerative disease in a subject. The assays, methods, and/or devices described herein can be configured to detect GAS5 long-coding RNAs and/or expression thereof in a sample from a subject.

First claim

We claim:

1. A method of treating Alzheimer's disease, diabetes, or diabetes and Alzheimer's disease in a subject in need thereof, the method comprising:
administering a therapeutically effective amount of a compound having a structure of formula 1

wherein R 1 is a methyl, an isobutane, a phenyl, an indole, or a butanamine,
wherein R 2 is an ethylbenzene, an ethylcyclohexane, an isopentane, a phenyl, a propanamine, or a methylcyclopropane,
wherein R 3 is a methylcyclopropane, a propionic acid, an ethylbenzene, or a propanamine
wherein R 4 is a butanamine, a propionic acid, or a phenyl,
wherein R 5 is a methylcyclopropane, a propionic acid, or an ethylbenzene,
wherein R 6 is a phenyl, a propionic acid, an isobutene, and
wherein R 7 is a phenyl, a propionic acid, a butanamine, or a methyl;
or a pharmaceutical formulation thereof, to the subject in need thereof.

2. The method of claim 1 , wherein the compound has a structure according to any one of Formulas 3-4, 6-19,

3. The method of claim 2 , wherein the compound is capable of binding a GAS5 long non-coding RNA.

4. The method of claim 3 , wherein the GAS5 long non-coding RNA has a sequence that is 90%-100% identical to SEQ ID NO: 1.

5. The method of claim 2 , wherein administering occurs via oral, rectal, intraocular, inhaled, intranasal, topical, vaginal, parenteral, subcutaneous, intramuscular, intravenous, or intradermal administration.

6. The method of claim 1 , wherein the compound is capable of binding a GAS5 long non-coding RNA.

7. The method of claim 6 , wherein the GAS5 long non-coding RNA has a sequence that is 90%-100% identical to SEQ ID NO: 1.

8. The method of claim 1 , wherein a pharmaceutical formulation is administered to the subject in need thereof and the pharmaceutical formulation further comprises an agent selected from the group consisting of: antisense or RNA interference molecules, chemotherapeutics, antineoplastic agents, hormones, antibiotics, antivirals, immunomodulating agents, antinausea, pain modifying agents, anti-inflammatory agents, antipyretics, antibiotics, antibodies, antibody fragments, and any combination thereof.

9. The method of claim 1 , further comprising contacting a sample from the subject in need thereof or component thereof with a capture molecule, wherein the capture molecule is configured to specifically bind to a biomarker, wherein the biomarker is gas5 (SNHG2); and detecting specific binding of the biomarker to the capture molecule.

10. The method of claim 9 , wherein the step of detecting specific binding of the biomarker to the capture molecule is performed using a method comprising a technique selected from the group consisting of: array polymerase chain reaction (PCR), quantitative PCR (qPCR), real-time PCR, real-time qPCR, reverse-transcription PCR (RT-PCR), real-time RT-PCR, RT-qPCR, real-time RT-qPCR, digital PCR (dPCR), RNA flare, (LATE)-PCR, RNA flow cytometry, nucleotide sequencing, cell-based RNA detection assays, in situ hybridization, northern blot analysis, and any combination thereof.

11. The method of claim 9 , wherein the capture molecule has a sequence that is 95%-100% identical to any one of SEQ ID NOs.: 2-3.

12. The method of claim 1 , wherein the subject is greater than 45 years of age.

13. The method of claim 1 , wherein the subject is less than 45 years of age.

14. The method of claim 1 , wherein the subject has or is suspected of having diabetes.

Assignees

• Patel Niketa A
• Cai Jianfeng
• Univ South Florida

Inventors

• Patel Niketa A
• Cai Jianfeng

Classifications

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• A61K31/33

  Heterocyclic compounds · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/404 Primary

  Indoles, e.g. pindolol · CPC title